Treatment of Asthma in Tobacco Smokers

Puri S and Mohanty B

Department of Biotechnology, Faculty of Science and Humanities, SRM University, Chennai, Tamil Nadu, India

Corresponding author: Puri S, Department of Biotechnology, Faculty of Science and Humanities, SRM University, Chennai, Tamil Nadu, India, Tel: +919882668649; E-mail: sanikapuris@gmail.com

Received date: March 18, 2018; Accepted date: March 21, 2018; Published date: March 27, 2018

Copyright: © 2018 Puri S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: Asthma; Cigarette; Respiration

Short Commentary

Smoking cigarette particularly affects persons with asthma. Asthma is the most common respiratory disease, occurs due to allergic inflammations in the bronchial tubes of lungs. Since prevalence of smoking is increasing, constant inhalation of tobacco stimulates the mucous glands in the bronchial tubes which gives access to the mucus and leads to symptoms like mucus production, dyspnea (shortness of breath), wheezing, cough and phlegm [1,2].

In asthma, contraction of muscles and swelling around the bronchial tubes creates breathing problems. Most cigarette smokers with the disease develop an irreversible narrowing in the bronchial passage causing them to face permanent difficulty in breathing, smoke-induced lung disease, emphysema and chronic bronchitis. On average, adults who experience asthmatic problems after age 50 mostly have a past history of smoking cigarettes. In most developed countries nearly 25% adults with respiratory illness are cigarette smokers. Active cigarette smokers with asthma might have severe symptoms, major reduction in lung function, and increase in corticosteroids sensitivity.

Smoking cigarettes might reconstruct inflammation associated with asthma, though there is little data about airway obstruction in smokers but compared to non-smokers a combination of both heightened and suppressed inflammatory responses are found in smokers.

Chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) are the common type of chronic airway diseases. While asthma the airway disorder mainly starts in childhood, smoking is not directly responsible for its cause. Recent research studies have found enough evidences, which proves there is an adverse effect of smoking on symptoms of asthma [3-6]. Both active and passive (exposure to environmental tobacco smoke) tobacco smoking have shown to increase exacerbation of asthma.

Onset of asthma in smokers

Some studies have shown that active smoking can be involved in the development of asthma [7-12]. The development of asthma-like symptoms in asymptomatic teenagers (over a 6 years period) has been associated with tobacco smoking (active), along with few cases of bronchial hyper responsiveness to methacholine and atopy [8]. In a study involving population size of 15813 adults, examined under respiratory questionnaire resulted in presence of maximum number of tobacco smokers (95%) as compared to non-smokers [10]. Strong association of smoking with the development of asthma was found to be common amongst individuals [7]. This study also proves that smoking can be a major risk factor for onset of asthma in older adults [9]. The arginine-14 genotype and β2-adrenergic receptor gene polymorphism, shows an inclination in the risk of asthma among active smokers compared with non-smokers [13]. In another experiment the risk factors associated with asthma among cigarette smokers have indicated that asthma which develops before starting smoking is associated with atopy and asthma which develops after initiating smoking is connected with lowering of forced expiratory volume [14].

Asthma: Effects and control

Cigarette smokers face high rate of morbidity and mortality due to development of asthma as compared with never-smokers. Asthma developed in smokers had more severity of symptoms as compared to non-smokers and need instant medications [15-18]. Major broncho constriction is developed due to smoking a cigarette, although smoking does not act as an acute allergen in all patients [19]. Inhalation of cigarette is directly related to the immediate response of forced expiratory volume (FEV), which indicates that asthmatic smokers with poor lung function can be vulnerable to the acute effect of tobacco smoke. Smokers with atopic asthma are likely to be less responsive towards inhaled adenosine compared to non-smokers which shows the differences in airway inflammation [20,21].

Treatment of asthma in smokers

For cessation of smoking, different and alternative treatments of inhaled corticosteroids are required for the patients who have persistent symptoms. Non-corticosteroid therapy in the treatment of asthma in smokers does not have much evidences, but there are many recently developed drugs, along with several under developed drugs which may produce efficient results in patients (active smokers) suffering from asthma.

β2 receptor agonist along with corticosteroid (inhaled) have shown efficient effects in the treatment of asthma, also this combination have shown effective results in the treatment of COPD [22,23]. The above mentioned combination of drugs suppresses the inflammation associated with COPD and asthma [24,25]. The possibly the combination of these drugs may show efficient results in the treatment of asthma in smokers. Activation of HDAC due to theophylline (low dose) suppresses the inflammation (theophylline is recruited by corticosteroids [26]. In vitro experiments have shown that theophylline can reverse the restraining effect of smoking on HDAC and hence can regenerate sensitivity of corticosteroid in asthmatic smokers [27].

Cilomilast and rolflumilast are phosphodiesterase-4 inhibitors which are effective drugs that can treat COPD (Table 1). Inhibitory activity of the phosphodiesterase-4 inhibitors can be the effective compounds that can prove to be a potent drug for treatment of asthma and smokers [28].
Table 1: Available drugs for the treatment of smoking.

| Drugs                  | Dosage                                          | Common adverse effects (CSE)                                      | Advantages                                           | Disadvantages                                      |
|------------------------|-------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------|
| Nicotine patch         | If<10 cig/day-21 mg                             | Skin irritation and insomnia                                      | Easy to use and steady nicotine level                | Slow release and not to be used during cravings    |
|                        | If>10 cig/day-14 mg                             |                                                                   |                                                      |                                                    |
| Varenicline            | 4 days-0.5 mg/day                               | Nausea, insomnia and abnormal dreams                             | Dual action-Relieves withdrawal and blocks reward from smoking | Psychiatric effects                                |
| Nicotine lozenge       | First Cigarette>30 minutes after waking-2 mg/h | Hiccups and heartburn                                            | User controls nicotine dose                          | No food or drink 30 minutes before use             |
|                        | First Cigarette<30 minutes after waking-4 mg/h |                                                                   |                                                      |                                                    |
| Nicotine nasal spray   | 1-2 hours: Once/nostril                         | Nasal irritation, cough, sneezing, teary eyes                    | Most rapid nicotine delivery                         | Local irritation                                    |
| Nicotine inhaler       | Inhalation as needed: 24-100 mg/24 hours        | Mouth, throat irritation                                         | User controls nicotine dose; cigarettes             | Frequent puffing required                          |
|                        |                                                  |                                                                  | oral substitute                                      |                                                    |
| Bupropion SR           | If<25 cig/day-2 mg/h                            | Mouth irritation and heartburn                                   | Cigarette substitute                                 | Dental damage and no food or drink 30 minutes before use |
|                        | If>25 cig/day-4 mg/h                            |                                                                  |                                                      |                                                    |
| Nicotine gum            |                                                  |                                                                  |                                                      |                                                    |
|                        | If<10 cig/day-21 mg                             | Skin irritation and insomnia                                      | Easy to use and steady nicotine level                | Slow release and not to be used during cravings    |
|                        | If>10 cig/day-14 mg                             |                                                                   |                                                      |                                                    |

Table References:

1. Kim H, Mazza J (2011) Asthma. Allergy Asthma Clin Immunol 7: 1-9.
2. Chatkin JM, Dullius CR (2016) The management of asthmatic smokers. Asthma Res Pract 20: 2.
3. Flodin U, Jonsson P, Ziegler I, Axelsson O (1995) An epidemiologic study of bronchial asthma and smoking. Epidemiology 6: 503-505.
4. Siroz V, Pin I, Oryszczyn MP, Le Moul N, Kauffman F (2000) Relationships of active smoking to asthma and asthma severity in the EGEA study. Eur Respir J 15: 470-477.
5. Spears M, Cameron E, Chaudhuri R, Thomson NC (2010) Challenges of treating asthma in people who smoke. Expert Rev Clin Immunol 6: 257-268.
6. Jindal SK, Gupta D (2004) The relationship between tobacco smoke and bronchial asthma. Indian J Med Res 120: 443-453.
7. Plaschke P, Janson C, Normann E, Bjorngerst E, Ellbjor S, et al. (2000) Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Am J Repir Crit Care Med 162: 920-924.
8. Rasmussen FSHC, Lambrechtsen J, Hanssen HS, Hansen NC (2000) Impact of airway lability, atopy, and tobacco smoking on the development of asthma-like symptoms in asymptomatic teenagers. Chest 117: 1330-1335.
9. Kim Y, Kim SH, Tak YJ (2002) High prevalence of current asthma and active smoking effect among the elderly. Clin Exp Allergy 32: 1706-1712.
10. Toren K, Hermansson B (1999) Incidence rate of adult-onset asthma in relation to age, sex, atopy and smoking: A Swedish population-based study of 15813 adults. Int J Tuberc Lung Dis 3: 192-197.
11. Vesterinen E, Kaprio J, Koskenvuo M (1988) Prospective study of asthma in relation to smoking habits among 14729 adults. Thorax 43: 534-539.
12. Troisi R, Speizer F, Rosner B, Trichopoulos D, Willet W (1995) Cigarette smoking and incidence of chronic bronchitis and asthma in women. Chest 108: 1557-1561.
13. Wang ZCC, Niu T, Wu D (2001) Association of asthma with beta2-adrenergic receptor gene polymorphism and cigarette smoking. Am J Respir Crit Care Med 163: 1404-1409.
14. Raherison C, Baldi I, Tunon-De-Lara JM, Taytard A, Annesi-Maesano I (2003) Asthma phenotypes according to the timing of smoking onset in young adults. Int J Tuberc Lung Dis 7: 84-92.
15. Althuis M, Sexton M, Prybylski D (1999) Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 36: 257-264.
16. Siroz V, Pin I, Oryszczyn MP, Le Moul N, Kauffman F (2000) Relationships of active smoking to asthma and asthma severity in the EGEA study. Eur Respir J 15: 470-477.
17. Sippel JM, Pedala KL, Vollmer WM, Buist AS, Osborne ML (1999) Associations of smoking with hospital-based care and quality of life in patients with obstructive airway disease. Chest 115: 691-696.
18. Gallefoss F, Bakke P (2003) Does smoking affect the outcome of patient education and self-management in asthmatics? Patient Educ Couns 49: 91-97.
19. Higenbottam T, Feyeraband C, Clark T (1980) Cigarette smoking in asthma. Br J Dis Chest 74: 279-284.
20. Jensen E, Dahl R, Steffensen F (2000) Bronchial reactivity to cigarette smoke, relation to lung function, respiratory symptoms, serum-immunoglobulin E and blood eosinophil and leukocyte counts. Respir Med 94: 119-127.
21. Oosterhoff Y, Jansen M, Postma D, Koeter G (1993) Airway responsiveness to adenosine 5' monophosphate in smokers and nonsmokers with atopic asthma. J Allergy Clin Immunol 92: 773-776.
22. Barnes P (2002) Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 19: 182-191.
23. Calverley P, Pauwels R, Vestbo J (2003) Combination salmeterol and fluticasone in the treatment of chronic obstructive pulmonary: A randomised controlled trial. Lancet 361: 449-456.

24. British Thoracic Society, Scottish Intercollegiate Guidelines Network (2003) British guidelines on the management of asthma. Thorax 58: 1-194.

25. Johnson M, Rennard S (2001) Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 120: 258-270.

26. Ito K, Caramori G, Cosio M, Chung K, Adcock IM, et al. (2002) A molecular mechanism of action of theophylline: Induction of histone deacetylase to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99: 8921-8926.

27. Ito K, Lim S, Chung KF, Barnes PJ, Adcock I (2002) Theophylline enhances histone deacetylase activity and restores glucocorticoid function during oxidative stress. Am J Respir Crit Care Med 165: 625.

28. Compton C, Gubb J, Nieman R (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose ranging study. Lancet 353: 265-270.